Quantity of suitable patients: CDEC mentioned the uncertainty in the amount of individuals with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be categorised as acquiring deli… Read More